A Phase 1, Randomized, Double Blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06730512 After Single And Multiple Ascending Intravenous Infusion Or Subcutaneous Administration To Healthy Adult Subjects And An Open-label Evaluation In Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 28 May 2018
At a glance
- Drugs PF-06730512 (Primary) ; PF-06730512 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 18 May 2018 Status changed from recruiting to completed.
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.
- 11 May 2017 New trial record